论文部分内容阅读
目的:探讨帕金森病(PD)伴发焦虑的相关因素。方法:采用贝克焦虑量表(BAI)将入组60例PD患者分为焦虑和非焦虑组。记录两组患者基本情况及用药情况。选用帕金森病统一评价量表(UPDRS)和改良Hoehn&Yahr(H&Y)分期评价患者运动症状;选用蒙特利尔认知评估量表(MOCA)、贝克抑郁量表(BDI)、PD睡眠量表(PDSS)、Epworth嗜睡量表(ESS)和PD自主神经症状量表(SCOPA-AUT)评价患者非运动症状。结果:基本情况及运动症状方面,焦虑组与非焦虑组间差异无统计学意义。PD药物使用方面,焦虑组金刚烷胺的日剂量及左旋多巴等效日剂量(LEDD)低于非焦虑组(P<0.05)。非运动症状方面,焦虑组BDI、PDSS和SCOPA-AUT得分高于非焦虑组(P<0.05)。回归分析示,BAI得分与BDI、SCOPA-AUT得分呈正相关,与LEDD呈负相关。结论:抑郁和自主神经功能障碍是PD焦虑的危险因素,LEDD是PD焦虑的保护因素。
Objective: To investigate the related factors of Parkinson’s disease (PD) associated with anxiety. Methods: Sixty patients with PD were divided into anxiety group and non-anxiety group using Baker’s anxiety scale (BAI). Record the basic situation and medication of two groups of patients. The motility of patients was assessed by UPDRS and Hoehn & Yahr (H & Y) staging. Montreal Cognitive Assessment Scale (MOCA), Bark Depression Scale (BDI), PD Sleep Scale (PDSS) Epworth Sleepiness Scale (ESS) and PD Autonomic Nervous Symptom Inventory (SCOPA-AUT) were used to evaluate non-motor symptoms. Results: There was no significant difference between anxiety group and non-anxiety group in the basic situation and motor symptoms. PD drug use, anxiety group amantadine daily dose and levodopa equivalent daily dose (LEDD) was lower than non-anxiety group (P <0.05). In non-motor symptoms, scores of BDI, PDSS and SCOPA-AUT in anxiety group were higher than those in non-anxiety group (P <0.05). Regression analysis showed that BAI score was positively correlated with BDI and SCOPA-AUT scores, and negatively correlated with LEDD. Conclusion: Depression and autonomic dysfunction are the risk factors of PD anxiety. LEDD is the protective factor of PD anxiety.